News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hanmi Pharmaceutical, Co., Ltd Does Not Infringe AstraZeneca PLC (AZN)'s Nexium -U.S. Appeals Court


12/20/2013 7:33:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The drug company AstraZeneca PLC lost a bid on Thursday to defend its widely used heartburn drug Nexium when an appeals court ruled that a new drug from Hanmi Pharmaceuticals did not infringe on Nexium patents. The U.S. Court of Appeals for the Federal Circuit upheld a lower court's ruling that Hanmi did not infringe on AstraZeneca's patent since the South Korean company uses different salts in making its products. The Federal Circuit issued an injunction against the Hanmi drug in August, but lifted it in September, AstraZeneca said earlier this week. Hanmi has won FDA approval for the drug, AstraZeneca said.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES